Lead Product(s) : MT-301
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Myeloid Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through this agreement, Myeloid de-risks the development of its candidates by leveraging Acuitas’ science and proven regulatory, to rapidly translate Myeloid’s innovation to patients. The MT-301 and MT-302 programs will utilize Acuitas’ LNP deliver...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 19, 2022
Lead Product(s) : MT-301
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Myeloid Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement